Skip to main content

Table 2 Metabolic toxicities

From: Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

Toxicity Temsirolimus (n = 31) Everolimus (n = 44) Time to highest toxicity grade, days Highest absolute change from baseline (%)
All grade n (%) Grade 3/4 n (%) All grade n (%) Grade 3/4 n (%) Median (range) Median (range)
Lymphopenia 13 (42) 4 (13) 25 (57) 9 (20) 56 (28; 644) −31 (−79; 168)
Increase in serum creatinine 14 (45) - 27 (61) - 90 (28; 420) 9.5 (−32; 78)
Hyperglycemia 9 (29) 2 (6) 24 (54) 6 (14) 56 (28; 756) 18 (−44; 346)
Hypophosphatemia 2 (6) 1 (3) 11 (25) 3 (7) 56 (28; 168) −22 (−55; 16)
Increase in ASAT 4 (13) - 14 (32) 1 (2) 28 (14-; 280) 47 (−75; 552)
Increase in ALAT 2 (6) - 14 (32) 2 (4) 28 (28; 308) 75 (−68; 1883)
Hypercholesterolemia 13 (42) - 31 (70) 3(7) 28 (28; 392) 32 (−51; 125)
Hypertriglyceridemia 14 (45) - 31 (70) - 56 (14; 224) 85 (−58; 375)
  1. ASAT aspartate aminotransferase, ALAT alanine aminotransferase